Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA.
College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Curr Med Res Opin. 2021 Mar;37(3):367-375. doi: 10.1080/03007995.2021.1877124. Epub 2021 Feb 8.
Seven prospective real-world studies conducted in general practices in Belgium of antihypertensive treatment with valsartan-centric regimens were pooled to examine similarities and differences in determinants of blood pressure (BP) values (mmHg) and BP control rates between female and male patients.
Pooled analysis of a total evaluable sample of 17,044 patients, including 8273 (48.5%) women and 8771 men (51.5%) treated over approximately 90 days with valsartan-centric regimens in second or later line. Hierarchical linear and logistic regressions were applied to identify patient- and physician-related determinants of BP outcomes and a potential physician class effect.
Reductions in BP (mmHg) over 90 days were similar for women and men, and so were changes in BP control rates. Approximately a quarter of the variance in 90 day BP values was attributable to a physician class effect. Both gender groups shared some patient- and physician-related determinants of BP outcomes, though often varying in degree of influence. Analyses also revealed gender-specific determinants. Among others, modifiable/manageable patient-related determinants included BP at hypertension diagnosis (proxy for time of diagnosis), risk factors, antihypertensive treatment and adherence; while among the physician-related determinants clinical experience in hypertension treatment was modifiable/manageable.
Valsartan-centric treatment regimens are associated with significant reductions in BP level and improvement in BP control in both women and men. The determinants revealed in modeling provide guidance to clinicians in the common and differential management of hypertension in female and male patients.
汇集了比利时普通诊所进行的七项前瞻性真实世界研究,这些研究均采用缬沙坦为中心的方案治疗高血压,以检查女性和男性患者的血压(mmHg)值和血压控制率的决定因素之间的异同。
对总共可评估的 17044 例患者的样本进行汇总分析,其中包括 8273 例(48.5%)女性和 8771 例男性(51.5%),这些患者在大约 90 天内接受缬沙坦为中心的方案进行二线或以上治疗。应用分层线性和逻辑回归来确定与血压结果相关的患者和医生相关的决定因素以及潜在的医生类别效应。
女性和男性的血压(mmHg)在 90 天内的降低幅度相似,血压控制率的变化也相似。大约四分之一的 90 天血压值的差异归因于医生类别效应。两个性别组都有一些与血压结果相关的患者和医生相关的决定因素,但影响程度往往不同。分析还揭示了性别特异性的决定因素。其中,可改变/可管理的患者相关决定因素包括高血压诊断时的血压(代表诊断时间)、危险因素、抗高血压治疗和依从性;而医生相关决定因素中,高血压治疗的临床经验是可改变/可管理的。
缬沙坦为中心的治疗方案可显著降低女性和男性的血压水平,并改善血压控制。模型中揭示的决定因素为临床医生在女性和男性患者中共同和差异化管理高血压提供了指导。